Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.

High-risk susceptibility genes explain <40% of the excess risk of familial ovarian cancer. Therefore, other ovarian cancer susceptibility genes are likely to exist. We have used a single nucleotide polymorphism (SNP)-tagging approach to evaluate common variants in 13 genes involved in cell cycle control-CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, and CDKN2D-and risk of invasive epithelial ovarian cancer. We used a two-stage, multicenter, case-control study. In stage 1, 88 SNPs that tag common variation in these genes were genotyped in three studies from the United Kingdom, United States, and Denmark ( approximately 1,500 cases and 2,500 controls). Genotype frequencies in cases and controls were compared using logistic regression. In stage 2, eight other studies from Australia, Poland, and the United States ( approximately 2,000 cases and approximately 3,200 controls) were genotyped for the five most significant SNPs from stage 1. No SNP was significant in the stage 2 data alone. Using the combined stages 1 and 2 data set, CDKN2A rs3731257 and CDKN1B rs2066827 were associated with disease risk (unadjusted P trend = 0.008 and 0.036, respectively), but these were not significant after adjusting for multiple testing. Carrying the minor allele of these SNPs was found to be associated with reduced risk [OR, 0.91 (0.85-0.98) for rs3731257; and OR, 0.93 (0.87-0.995) for rs2066827]. In conclusion, we have found evidence that a single tagged SNP in both the CDKN2A and CDKN1B genes may be associated with reduced ovarian cancer risk. This study highlights the need for multicenter collaborations for genetic association studies.

[1]  E. Garrett,et al.  Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. , 1995, Cancer research.

[2]  A. Whittemore,et al.  Common variants in RB1 gene and risk of invasive ovarian cancer. , 2006, Cancer research.

[3]  D. Gertig,et al.  Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  D. Duggan,et al.  Recent developments in genomewide association scans: a workshop summary and review. , 2005, American journal of human genetics.

[5]  A. Spurdle,et al.  CYP17 promotor polymorphism and ovarian cancer risk , 2000, International journal of cancer.

[6]  Malcolm C Pike,et al.  Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. , 2005, Journal of the National Cancer Institute.

[7]  L. Kolonel,et al.  Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  A. Spurdle,et al.  BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk , 2003, International journal of cancer.

[9]  A. Spurdle,et al.  No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. , 2001, Carcinogenesis.

[10]  R. Berkowitz,et al.  Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. , 2002, Cancer research.

[11]  A. Berchuck,et al.  Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. , 1998, British Journal of Cancer.

[12]  A. Whittemore,et al.  Common variants in mismatch repair genes and risk of invasive ovarian cancer. , 2006, Carcinogenesis.

[13]  A. Sood,et al.  The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. , 1997, Cancer gene therapy.

[14]  R. Nelson,et al.  The HRAS1 minisatellite locus and risk of ovarian cancer. , 2000, Cancer research.

[15]  A. Spurdle,et al.  The prohibitin 3' untranslated region polymorphism is not associated with risk of ovarian cancer. , 2003, Gynecologic oncology.

[16]  J. Lancaster,et al.  p53 polymorphism in ovarian and bladder cancer , 1995, The Lancet.

[17]  Funk Jo,et al.  Cancer cell cycle control. , 1999 .

[18]  G. Giles,et al.  Androgen receptor exon 1 cag repeat length and risk of ovarian cancer , 2000, International journal of cancer.

[19]  A. Whittemore,et al.  STK15 polymorphisms and association with risk of invasive ovarian cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  I. Nagata,et al.  Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer , 2002, International journal of cancer.

[21]  G. Abecasis,et al.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.

[22]  A. Whittemore,et al.  Polymorphisms in DNA repair genes and epithelial ovarian cancer risk , 2005, International journal of cancer.

[23]  Christopher A. Haiman,et al.  Choosing Haplotype-Tagging SNPS Based on Unphased Genotype Data Using a Preliminary Sample of Unrelated Subjects with an Example from the Multiethnic Cohort Study , 2003, Human Heredity.

[24]  A. Kibel,et al.  CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. , 2003, Cancer research.

[25]  N. Umesaki,et al.  The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[27]  S. Chow,et al.  Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer , 2004, International Journal of Gynecologic Cancer.

[28]  D. Easton,et al.  Risk prediction models for familial breast cancer. , 2006, Future oncology.

[29]  R. Vierkant,et al.  Estrogen Bioactivation, Genetic Polymorphisms, and Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[30]  Minoru Yoshida,et al.  The Cytoplasmic Shuttling and Subsequent Degradation of p27Kip1 Mediated by Jab1/CSN5 and the COP9 Signalosome Complex* , 2002, The Journal of Biological Chemistry.

[31]  K. Shigemasa,et al.  Cyclin D1 Overexpression and p53 Mutation Status in Epithelial Ovarian Cancer , 1999, The Journal of the Society for Gynecologic Investigation: JSGI.

[32]  N. Ragni,et al.  Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[34]  Ralph Weissleder,et al.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Kreienberg,et al.  p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer , 1995, The Lancet.

[36]  Frank Dudbridge A note on permutation tests in multistage association scans. , 2006, American journal of human genetics.

[37]  B. Ponder,et al.  The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. , 1999, American journal of human genetics.

[38]  T. Löning,et al.  p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper‐methylation or mutation in endometrioid and mucinous tumors , 1998, International journal of cancer.

[39]  D. Levine,et al.  The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. , 2001, Cancer research.

[40]  R. Weinberg,et al.  Control of the cell cycle and apoptosis. , 1999, European journal of cancer.